TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07277582: Evaluation of the Efficacy and Safety of THRV-1268 in Participants With Long QT Syndrome Type 2 (LQTS2) and Type 3 (LQTS3)

Sponsor: Thryv Therapeutics, Inc. · Phase: PHASE2/PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 84 pts

Competing Trials Overlap

7 Active Trials

Excess Burn Exposure

$1,539,152

Rescue Site Savings

+$1,012,600

Unlock Full NCT07277582 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07277582 Rescue Dossier →